This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Angelo Antonini, AD/PD 2022: α-Synuclein seeding activity in gastrointestinal biopsies of Parkinson’s disease patients

10 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 5th 2022

Gastrointestinal dysfunctions represent one of the main non-motor symptoms in Parksinon’s disease (PD). Prof. Angelo Antonini (Professor of Neurology, University of Padua, Padua, Italy) discusses a study that investigated α-Synuclein seeding activity in stomach-duodenum biopsies of PD patients by real-time quaking induced conversion (RT-QuIC) assay. The results suggest a deeper investigation in detection of α-Synuclein seeding activity in the early stages of PD in gastrointestinal biopsies via RT-QuIC as an early biomarker of disease.

The abstract entitled: ‘Detection of α-Synuclein Seeding Activity by RT-QUIC Assay in Gastrointestinal Biopsies of Patients with Advanced Parkinson’s Disease’ was presented at the International Conference of Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD), 13-15 October 2021.

Questions:

  1. What unmet needs exist in the detection of the prodromal phase of Parkinson’s disease (PD)? (0:20)
  2. What evidence is there to support the hypothesis that α-Synuclein seeding activity occurs in the gastrointestinal tract in PD? (3:32)
  3. What were the aims and methodology,  study findings? (5:49)
  4. What will be the next stages of this research? (8:13)

Disclosures: Prof. Angelo Antonini is a consultant for AbbVie, Bial, Biopharma, Britannia, Ever Pharma, UCB, Jazz Pharmaceuticals, Kyowa Kirin, Theravance, Roche, Zambon; receives grant/research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals,  Horizon 2020 – Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, and Movement Disorders Society.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of AD/PD 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup